<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952259</url>
  </required_header>
  <id_info>
    <org_study_id>M2019480</org_study_id>
    <nct_id>NCT04952259</nct_id>
  </id_info>
  <brief_title>Effect of Shexiang Tongxin Dropping Pills on Microcirculation in Patients With AMI</brief_title>
  <official_title>Evaluation of the Effect of Shexiang Tongxin Dripping Pills on Coronary Microcirculation in Patients With Acute Anterior Myocardial Infarction by Microcirculation Resistance Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, controlled clinical trial. Evaluation of microcirculation&#xD;
      resistance by index of microcirculation resistance to explore the protective effect of&#xD;
      Shexiang Tongxin dripping pills on microcirculation in patients with acute anterior&#xD;
      myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) is the best way to improve the prognosis of patients&#xD;
      with acute myocardial infarction (AMI), and ischemia-reperfusion injury (I/R) can damage the&#xD;
      vascular endothelium through complex mechanisms, leading to microcirculation dysfunction and&#xD;
      aggravation myocardial damage and affect the prognosis. Cell and animal experiments have&#xD;
      proved that Shexiang Tongxin Dropping Pill has anti-inflammatory, anti-oxidant, reducing I/R&#xD;
      damage, reducing infarct size, improving peripheral muscle microcirculation, and improving&#xD;
      coronary slow blood flow, but it lacks directive evidences of improved coronary&#xD;
      microcirculation in AMI patients. The microcirculation resistance index (IMR) is a parameter&#xD;
      to evaluate the microcirculation state obtained by the pressure/temperature guidewire during&#xD;
      PCI, which can accurately and quantitatively reflect the patient's coronary microcirculation&#xD;
      state. In this study, patients with acute anterior wall elevation ST-segment myocardial&#xD;
      infarction (STEMI) who were prospectively selected for direct PCI treatment were randomly&#xD;
      divided into treatment group and control group. The treatment group was given Shexiang&#xD;
      Tongxin Dropping Pills before PCI and received direct PCI treatment, the control group only&#xD;
      received direct PCI treatment. The IMR of the two groups was detected immediately after PCI,&#xD;
      and the differences in IMR values, myocardial injury markers and cardiac function parameters&#xD;
      between the two groups were analyzed. It is hoped to prove that Shexiang Tongxin dripping&#xD;
      pills have coronary microcirculation protection in acute anterior wall elevation ST-segment&#xD;
      myocardial infarction with undergoing direct PCI treatment, and the effect is rapid, so as to&#xD;
      provide a basis for optimizing AMI treatment strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IMR</measure>
    <time_frame>detected immediately after percutaneous coronary intervention</time_frame>
    <description>microcirculation resistance index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury markers</measure>
    <time_frame>72 hours</time_frame>
    <description>cardiac enzymes and troponin T</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shexiang Tongxin dripping pills + routine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>routine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shexiang Tongxin Dropping Pills + routine treatment</intervention_name>
    <description>oral+percutaneous coronary intervention</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>drugs and surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>routine treatment</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old, no gender limit;&#xD;
&#xD;
          -  Anterior wall STEMI within 12 hours of onset (diagnostic criteria: ischemic chest pain&#xD;
             lasting ≥30min; ST-segment elevation or new left bundle branch block in two or more&#xD;
             adjacent leads on the ECG; with or without Elevated myocardial markers), emergency PCI&#xD;
             treatment is planned;&#xD;
&#xD;
          -  Infarct-related coronary vascular anatomy is suitable for PCI treatment;&#xD;
&#xD;
          -  Agree and cooperate to participate in this research, and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of myocardial infarction history;&#xD;
&#xD;
          -  The arteries related to infarction have received PCI in the past;&#xD;
&#xD;
          -  Past CABG history;&#xD;
&#xD;
          -  Killip grade of cardiac function ≥ grade III or cardiogenic shock;&#xD;
&#xD;
          -  Systolic blood pressure ≤90mmHg;&#xD;
&#xD;
          -  Bradycardia, heart rate &lt;60 beats/min, or atrioventricular block of degree II or more;&#xD;
&#xD;
          -  Allergic to Shexiang Tongxin Dropping Pills&#xD;
&#xD;
          -  Past history of asthma or severe COPD;&#xD;
&#xD;
          -  Severe liver and kidney dysfunction;&#xD;
&#xD;
          -  Participate in other clinical trials within 3 months;&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liyun He</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liyun He</last_name>
    <phone>+8613901132937</phone>
    <email>hly26@126.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

